profit from every $100 of sales.
$0$100
Twist Bioscience
$111.60-2.29% today
+273.2% in 1 year
1-year low $25.451-year high $205.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Twist Bioscience sold, what it kept, and what it did with the cash.
Sales went from $204 million in 2022 to $377 million in 2025, with -$77.7 million of profit last year.
SalesProfit
Twist Bioscience vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Twist Bioscience | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Twist Bioscience's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 90 | 132 | 204 | 245 | 313 | 377 | |
| 29 | 52 | 84 | 90 | 133 | 191 | |
| -140 | -153 | -249 | -207 | -176 | -136 | |
| -132 | -144 | -212 | -178 | -144 | -111 | |
| -140 | -152 | -218 | -205 | -209 | -78 | |
| -3.57 | -3.15 | -4.04 | -3.60 | -3.60 | -1.30 | |
| 31.8% | 39.1% | 41.4% | 36.6% | 42.6% | 50.7% | |
| -155.5% | -115.4% | -122.3% | -84.4% | -56.2% | -36.2% | |
| -155.3% | -114.9% | -107.0% | -83.5% | -66.7% | -20.6% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 399 | 702 | 961 | 776 | 614 | 642 |
| Cash | 94 | 466 | 379 | 286 | 226 | 183 |
| Total debt | – | – | 95 | 94 | 85 | 76 |
| Total liabilities | 63 | 121 | 172 | 153 | 142 | 169 |
| 336 | 581 | 789 | 623 | 473 | 473 | |
| 39 | 48 | 54 | 57 | 58 | 60 | |
| -32.6% | -20.9% | -20.4% | -22.8% | -24.9% | -19.6% | |
| -41.6% | -26.2% | -27.6% | -32.8% | -44.2% | -16.4% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -142 | -112 | -124 | -142 | -64 | -48 | |
| 10 | 27 | 102 | 28 | 5 | 28 | |
| -152 | -139 | -226 | -170 | -69 | -76 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | 8 | 4 | 4 | 0 | |
| 17 | 37 | 80 | 30 | 51 | 64 |
Valuation
- –
- –
- –
- 16.9×
- 19.6×
- –
- –
- -1.0%
- -1.0%
- 0.0%
Profitability
- 50.7%
- -36.2%
- -20.6%
- -14.2%
- -20.1%
- -22.5%
- -17.5%
- -12.0%
- -25.0%
- 17.6%
Growth
- +33.1%
- –
- −9.3%
- –
- +3.5%
Financial health
- -1.0×
- 0.16
- 14.2%
- –
- 3.64
- 2.42
- 0.61
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 19%of 952
Bottom 8%of 884
Top 16%of 886
Bottom 33%of 987
What analysts expect
- Average price target
- $52.33
- Range
- $50.00 – $55.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 4, 2026 | -0.62 | -0.49 | −26.5% |
| Feb 2, 2026 | -0.50 | -0.48 | −4.2% |
| Nov 14, 2025 | -0.45 | -0.50 | +10.0% |
| Aug 4, 2025 | -0.47 | -0.54 | +13.0% |
| May 5, 2025 | -0.66 | -0.56 | −17.9% |
| Feb 3, 2025 | -0.53 | -0.62 | +14.5% |
| Nov 18, 2024 | -0.59 | -0.71 | +17.4% |
| Aug 2, 2024 | -0.86 | -0.79 | −8.9% |
News
Trumpflation Is Evolving, and There's a New Twist That Threatens to Sink StocksYahoo Finance · Oct 21, 20263 global ETFs edge SCHD on income, but there's a twistYahoo Finance · Oct 20, 2026Morgan Stanley finds a new twist in Microsoft's AI storyYahoo Finance · Oct 15, 2026Bitcoin beats Gold, SPY, Silver, QQQ in Iran war: Here's the twistSeeking Alpha · Sep 29, 2026What Needs To Be True To Buy Twist Bioscience Stock Now?Yahoo Finance · Sep 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
39No pass
Philip Fisher
48No pass
Peter Lynch
70Pass
Joel Greenblatt
0No pass
Charlie Munger
37No pass
Terry Smith
42No pass
Questions about Twist Bioscience
Is Twist Bioscience a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Twist Bioscience AI analysis
What does Twist Bioscience do?
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It is in Biotechnology, based in South San Francisco, CA, United States, with 979 employees.
Does Twist Bioscience pay a dividend?
No. Twist Bioscience does not pay a dividend at the moment; in 2025 it returned $16,000 to shareholders by buying back its own shares.
Is Twist Bioscience stock halal?
Yes. Twist Bioscience passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Twist Bioscience stock done over the past year?
Up 273.2% over the past twelve months, to $111.60. It traded between $25.45 and $205.00 and is 45.6% below its high.
Who are Twist Bioscience's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Twist Bioscience's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.